When Gilead Science, Inc.’s (GILD) CEO Daniel O’Day released his March 28 open letter stating the firm’s new wonder-drug (the antiviral Remdesivir) could work against COVID-19, he had every hope the company's share price would soar - and he was right. But there's more to this stock's story.
* This article was originally published here
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment